MedTrace Logo

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

NCT00969319 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2015-01-19

No results posted yet for this study

Summary

The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.

Conditions

Interventions

BIOLOGICAL

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Patients under daily life treatment receiving Kogenate according to local drug information.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2013-02-28
Completion
2014-02-28

Countries

  • Mexico
  • Venezuela

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969319 on ClinicalTrials.gov